Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ornithine alpha ketoglutarate (OKG) is a salt formed from the amino acid ornithine and alpha-ketoglutarate, a precursor to glutamine. It is used as a dietary supplement and in clinical nutrition, particularly for wound healing, burns, trauma recovery, and muscle protein synthesis. OKG may alter amino acid metabolism in the body and stimulate anabolic hormone secretion (notably insulin and growth hormone), which can promote protein synthesis and reduce muscle catabolism. Its mechanism of action is not fully understood but involves increased production of metabolites such as glutamine, polyamines, arginine, and ketoacids. OKG has been administered both orally and intravenously in various clinical settings[1][2][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ornithine alpha ketoglutarate.